All In Biotech

Drug Trial Radar · NCT05827653

MAD Study of NX210c

A Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose (MAD) Study in Healthy Elderly Volunteers and Alzheimer's Disease (AD) Patients to Investigate the Safety and Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) Effects of Multiple Intravenous Infusions of NX210c

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Dec 5, 2022

Primary completion

Apr 29, 2023

Study completion Oct 2, 2023

Sponsor

Lead sponsor
Axoltis PharmaIndustry
Sponsor type
Industry
Collaborators
Centre for Human Drug Research, Netherlands
First posted
Apr 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.

Conditions

  • Healthy Elderly

Interventions

  • NX210cDrug

    3 times a week, for 28 days

  • PlaceboDrug

    3 times a week, for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity and incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), suspected unexpected serious adverse reactions (SUSARs)Time frame: Up to 16 days after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Human Drug Research

    Leiden, South Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.